scholarly journals Avoiding biopsy in iron deficiency anemia is not a cost-effective approach

2012 ◽  
Vol 104 (6) ◽  
pp. 334-334
Author(s):  
Sauid Ishaq ◽  
Rizwan Mahmood ◽  
Vicenzo Vilannacci ◽  
Gabrio Bassotti ◽  
Kamran Rostami
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Cost Effective ◽  
Deficiency Anemia ◽  
Cost Effective Approach

scholarly journals Oral high-dose sucrosomial iron vs intravenous iron in sideropenic anemia patients intolerant/refractory to iron sulfate: a multicentric randomized study

2020 ◽  
Author(s):  
Giulio Giordano ◽  
Mariasanta Napolitano ◽  
Valeria Di Battista ◽  
Alessandro Lucchesi
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Randomized Study ◽  
Intravenous Iron ◽  
Cost Effective ◽  
Oral Iron ◽  
Iron Sulfate ◽  
Deficiency Anemia ◽  
High Dose ◽  
Iron Administration

AbstractIron deficiency anemia is among the most frequent causes of disability. Intravenous iron is the quickest way to correct iron deficiency, bypassing the bottleneck of iron intestinal absorption, the only true mechanism of iron balance regulation in human body. Intravenous iron administration is suggested in patients who are refractory/intolerant to oral iron sulfate. However, the intravenous way of iron administration requires several precautions; as the in-hospital administration requires a resuscitation service, as imposed in Europe by the European Medicine Agency, it is very expensive and negatively affects patient’s perceived quality of life. A new oral iron formulation, Sucrosomial iron, bypassing the normal way of absorption, seems to be cost-effective in correcting iron deficiency anemia at doses higher than those usually effective with other oral iron formulations. In this multicentric randomized study, we analyze the cost-effectiveness of intravenous sodium ferrigluconate vs oral Sucrosomial iron in patients with iron deficiency anemia refractory/intolerant to oral iron sulfate without other interfering factors on iron absorption.

scholarly journals Serum hepcidin and interleukin-6 as biochemical markers in differentiation of iron deficiency anemia and anemia of chronic disease

2018 ◽  
Vol 6 (6) ◽  
pp. 1922
Author(s):  
Sonal Vyas ◽  
Sanjeev Suman ◽  
Anil Kapoor ◽  
S. K. Nema
Keyword(s):  
Chronic Disease ◽  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Cost Effective ◽  
Average Concentration ◽  
Deficiency Anemia ◽  
Anemia Of Chronic Disease ◽  
Tissue Iron ◽  
Serum Hepcidin ◽  
Total Body

Background: Iron deficiency (ID) is the most prevalent nutritional deficiency and the most common cause of anemia in the world. It is defined as a reduction in total body iron to an extent that iron stores are fully exhausted and even some degree of tissue iron deficiency results. The Present study aims to compare the serum hepcidin and IL-6 levels in anemia of chronic disease (ACD) and iron deficiency anemia (IDA) groups and correlate the values of serum hepcidin levels with their serum ferritin levels and IL-6 levels.Methods: A total of 112 individuals were enrolled in the study. Samples for hematological evaluations were collected and estimation was carried out for biomarker using ELISA method(s) using specified kit(s) procured commercially. The statistical evaluation was done using SPSS version 24.0. Analysis of variance (ANOVA) and Pearson's correlation tests were used to compare the variables and to see the correlation between the different variables.Results: In present study, we compared the values of RBC count, Hb gm/dl, MCV, MCH, MCHC in ACD and IDA group. Serum Hepcidin, a marker of iron deficiency anemia was significantly low in case of IDA 33.23±12.46ng/mL, on the contrary in case of ACD group the serum hepcidin level was elevated 98.36±24.29ng/mL. It is found that IL- 6 plays an important role in the regulation of hepcidin as reflected especially in ACD and IDA groups. In case of IDA the level of IL6 was significantly reduced to an average concentration 7.62±3.51ng/mL on the contrary in case of ACD group the serum IL-6 level was elevated to 115.82±33.7ng/mL. Thus, it provides for conclusive differentiation or diagnosis of iron deficiency anemia and anemia of chronic disease.Conclusions: Serum Hepcidin can be used as a simple and cost effective diagnostic marker for differentiation of iron deficiency anemia and anemia of chronic disease.

scholarly journals The study of efficacy of injection iron sucrose in treatment of iron deficiency anemia in pregnancy

2019 ◽  
Vol 8 (6) ◽  
pp. 2444
Author(s):  
Akhileshwar Singh ◽  
Sanjay Singh ◽  
Anuj Sharma
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Cost Effective ◽  
Oral Iron ◽  
Iron Sucrose ◽  
Deficiency Anemia ◽  
Outpatient Basis ◽  
Study Population ◽  
Anaemia In Pregnancy ◽  
In Pregnancy

Background: Iron deficiency is the most common cause of anaemia in pregnancy amounting to almost 50% of pregnant ladies in India. All pregnant women, irrespective of haemoglobin status, should receive prophylactic doses of iron from second trimester. Iron sucrose has an advantage of being cost effective and readily available. The objective of this was to study the efficacy of injection Iron Sucrose in treatment of iron deficiency anaemia in pregnancy.Methods: About106 patients were given in injection iron sucrose in pregnancy, who had intolerance to oral iron or were non-compliant, in pre calculated (Ganzoni’s formula) doses and were followed up with rise in hemoglobin and ferritin after 6 weeks and at term.Results: Statistically significant increase in hemoglobin levels was observed at 6 weeks after initiation of treatment (9.689±0.821 gm% vs 10.906±0.775 gm%) as well as at term (mean 10.981±0.690 gm%). The serum ferritin levels too increased significantly at term (26.7 ng/mL±12.92 vs 65.34 ng/mL±15.73).Conclusions: Present study demonstrates that iron sucrose is an excellent option to treat iron deficiency anemia in patients where oral iron therapy has either failed or not suitable. It significantly increases hemoglobin levels in the study population. It is readily available in the market and can be infused on an outpatient basis.

Infants in the Second Year of Life Are Still at Significant Risk for Developing Iron Deficiency Anemia (IDA) and Should Be Treated with Prophylactic Iron Supplements.

Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4533-4533
Author(s):  
Yifat Nir ◽  
Yehuda Limoni ◽  
Michal Gordon ◽  
Asher Moser
Keyword(s):  
Iron Deficiency ◽  
Iron Deficiency Anemia ◽  
Ferritin Level ◽  
Cost Effective ◽  
Psychomotor Development ◽  
Deficiency Anemia ◽  
Ministry Of Health ◽  
Second Year Of Life ◽  
Second Year

Abstract Abstract 4533 Background Identifying and treating iron deficiency anemia (IDA) is recommended by the American Academy of Pediatrics, the CDC and a U.S. Preventive Services Task Force to prevent various long-term squeals such as delayed mental and psychomotor development. As the prevalence of IDA and Thalassemia is high in Israel, the ministry of health has instituted that all infants of 4-12 months of age be supplemented with an iron preparation at 3 mg/kg/day. Iron deficient infants are treated with 6mg/kg/day iron, and rechecked at 3 months. Aim of Study To determine the prevalence of IDA in infants in the second year of life Methods Study population consists of 1818 toddlers between 12 to 24 months, from eight clinics in the southern (Negev) district of Israel; four clinics of the Bedouin sector (1167 toddlers) and four of the Jewish sector (651 toddlers) Samples were collected during 2006 and 2007 from otherwise healthy individuals, as recommended by the ministry of health. Toddlers were eligible unless previously known to be suffering from a congenital anemia disorder. Anemia was defined as MCV < 70. Iron deficiency was defined by an increment in MCV at a repeat test within 6 months or a ferritin level below norm. Results Of the 968 males and 850 females (Mean age 16.9±3.4 months), 505 (27.8%) toddlers were found to be anemic. The prevalence of anemia was significantly higher amongst Bedouin toddlers, (37.5% vs. 10.3% in Jews, p=0.001), and Male gender (30.5% vs. 24.7% in females, p=0.006), highly significant for Jewish males (14.6% vs. 5.5% in Jewish females p<0.001). Anemic toddlers were significantly older than the non-anemic toddlers (17.3±3.4 months vs. 16.7±3.4, respectively, p=0.001). One hundred thirteen (22.3%) anemic infants had a follow-up test (average time 4.4 months), 81 of them had an improvement in MCV and 5 had a low ferritin level. The group of toddlers with IDA was determined at 76.1% of the anemic children. We found no significant difference in the execution of a follow-up test between sectors and genders. However, toddlers that underwent a second test were significantly younger, by an average of 3 months (p<0.001, 95% [CI]: 2.27-3.45 months). No differences in demographics gender, age or blood indices were found between the groups of infants who repeated the test and those without further data. Of the total sample population 20.1% were defined as IDA. Multivariate analysis of the anemia model revealed a significantly higher risk for developing IDA in the second year of life for Bedouin toddlers (27%) compared to Jewish toddlers (7.4%; OR: 3.7; 95% CI: 2.482-5.468), and for male toddlers compared to female. Conclusions A cost-effective screening program to prevent and treat IDA and other anemias in a high-risk population is cost effective and easily executed. Physicians need to be aware of IDA in order to implement an effective screen. With an overall prevalence of more than 1 in 5 infants suffering from IDA, and the very low probability of iron overload, our results clearly support the need to continue iron supplementation in the second year of life. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document